Abimmune Biopharma develops next-generation multi-specific and multi-functional protein drugs. We focus on unmet medical needs in respiratory viral infections and in oncology. Our lead drug in development, ResCovidin, is a universal prophylactic and therapeutic candidate against all variants of Covid-19 and other respiratory viruses.